Ana Ramírez-Sánchez

Ana Ramírez-Sánchez

Auto-generated profile, based on publicly available information

Ana Ramírez-Sánchez

Area of Physiology, Faculty Health Sciences, University Rey Juan Carlos, 28922, Alcorcón, Madrid, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Genes & Development
Verified
Journal Article
Open access
PDF file
ACAna Chocarro-Calvo
Ana Chocarro-Calvo
MJMiguel Jociles-Ortega
Miguel Jociles-Ortega
JGJosé Manuel García-Martinez
José Manuel García-Martinez
PLPakavarin Louphrasitthiphol
Pakavarin Louphrasitthiphol
SCSofia Carvalho-Marques
Sofia Carvalho-Marques
CGCustodia García-Jiménez
Custodia García-Jiménez
Interaction between the tumor microenvironment and cancer cell plasticity drives intratumor phenotypic heterogeneity and underpins disease progression and nongenetic therapy resistance. Phenotype-specific expression of the AXL receptor tyrosine kinase is a pivotal player in dormancy, invasion, and resistance to treatment. However, although the AXL ligand GAS6 is present within tumors, how AXL is activated in metastasizing cells remains unclear. Here, using melanoma as a model, we reveal that AXL is activated by exposure to human adipocytes and to oleic acid, a monounsaturated fatty acid abundant in lymph and in adipocytes. AXL activation triggers SRC-dependent formation and nuclear translocation of a β-catenin–CAV1 complex required for melanoma invasiveness. Remarkably, only undifferentiated AXLHighmelanoma cells engage in symbiosis with human adipocytes, in part by triggering WNT5a-mediated lipolysis, leading to AXL-dependent, but FATP-independent, fatty acid uptake and nuclear localization of the β-catenin–CAV1 complex. Significantly, human melanomas in the vicinity of adipocytes exhibit high levels of nuclear CAV1. The results unveil an AXL- and CAV1-dependent mechanism through which a nutritional input drives phenotype-specific activation of a prometastasis program. Given the key role of AXL in a broad range of cancers, the results offer major insights into the mechanisms of cancer cell dormancy and therapy resistance.

12 April 2025 in bioRxiv
Verified
Preprint
Open access
ARAna Ramírez-Sánchez
Ana Ramírez-Sánchez
MJMiguel Jociles-Ortega
Miguel Jociles-Ortega
JGJosé Manuel García-Martinez
José Manuel García-Martinez
ITIrene Torrens-Martínez
Irene Torrens-Martínez
Javier Martinez-UserosJavier Martinez-Useros
Javier Martinez-Useros
ACAna Chocarro-Calvo
Ana Chocarro-Calvo
The impact of the microenvironment on epigenetically plastic cancer cells underpins phenotypic heterogeneity, a major cause of metastatic dissemination and therapy resistance that together represent the primary cause of cancer-related death. Nutrient limitation is a key microenvironmental stress that can cause a phenotypic transition from proliferation to invasion via activation of the integrated stress response. However, whether and how the capacity to store and mobilize nutrients impacts phenotype-switching through metabolic buffering remains unknown. Here, using melanoma as a model, we reveal that the ability to accumulate and mobilize glycogen, that buffers glucose availability, plays a key role in phenotypic transitions in melanoma. While proliferative phenotype cells exhibit high levels of glycogen, invasion is marked by low glycogen levels. Significantly, an inability to store and metabolize glycogen leads to phenotype instability and a switch to invasion. Accordingly, glycogen levels inversely correlate with Clark levels in primary melanomas, with low expression of the glycogen phosphorylases PYGB/L and phosphoglucomutase 1 (PGM1) being associated with worse overall survival. The importance of metabolic buffering in suppressing phenotypic transitions likely extrapolates to other cancer types. Highlights: Melanoma phenotypes are distinguished by their ability to store and mobilize glycogen. Proliferative MITF High melanoma cells store glycogen to improve survival under stressful conditions. Inhibition of glycogen degradation impairs proliferation in MITF High melanoma cells. Lack of PGM1 drives invasion and metastatic dissemination.

15 July 2026 in The EMBO Journal
Verified
Journal Article
Open access
ARAna Ramírez-Sánchez
Ana Ramírez-Sánchez
MJMiguel Jociles-Ortega
Miguel Jociles-Ortega
JGJosé Manuel García-Martínez
José Manuel García-Martínez
ITIrene Torrens-Martínez
Irene Torrens-Martínez
JMJavier Martínez-Useros
Javier Martínez-Useros
ACAna Chocarro-Calvo
Ana Chocarro-Calvo
The impact of the metabolic microenvironment on epigenetically plastic cancer cells underpins phenotypic heterogeneity, a major cause of metastasis and therapy resistance. Nutrient limitation is a key microenvironmental stress, and can cause cells to transition from proliferative to invasive phenotypes, however, whether cancer cells have the capacity to delay phenotype switching remains unknown. Here, using melanoma as a model, we reveal that the ability to buffer glucose availability by accumulating and mobilizing glycogen can determine cancer cell phenotypic transitions. While proliferating cells contain high levels of glycogen, invasive cells are marked by depleted glycogen stores. Accordingly, the inability to store and metabolize glycogen leads to phenotype instability and a switch from proliferation to invasion. The amount of stored glycogen inversely correlates with tissue invasion depth in primary melanomas, and reduced expression of the glycogen phosphorylases PYGB/L and phosphoglucomutase 1 (PGM1) is associated with worse patient survival. Together, we identify metabolic glucose buffering as a determinant of invasive phenotype transitions in skin cancer, suggesting similar paradigms in other cancer types.